Reply: 99mTc-labelled Stealth liposomal doxorubicin (Caelyx®) in glioblastomas and metastatic brain tumours
2002

Reply on Imaging with Caelyx in Brain Tumours

Sample size: 30 publication Evidence: moderate

Author Information

Author(s): Koukourakis M I

Primary Institution: Democritus University of Thrace

Hypothesis

Does the simple labelling technique effectively label Caelyx for imaging in glioblastomas and metastatic brain tumours?

Conclusion

The imaging quality of 99mTc-DTPA-Caelyx is superior to that of 99mTc-DTPA alone in certain cancer patients.

Supporting Evidence

  • Imaging with 99mTc-DTPA was of unacceptably poor quality in some cases.
  • Liposomal imaging was superior to sestamibi in more than 10 glioma patients.
  • The study suggests that 99mTc-DTPA may label liposomes without internalization.

Takeaway

This study shows that a special way of tagging a cancer drug helps doctors see tumors better in some patients.

Methodology

The study compared imaging results from 30 lung cancer patients using different radio-pharmaceuticals.

Limitations

The study's findings are based on a limited number of patients and may not be generalizable.

Participant Demographics

Patients included were primarily those with non-small cell lung cancer and head and neck cancer.

Digital Object Identifier (DOI)

10.1038/sj.bjc.6600094

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication